AC Immune (NASDAQ:ACIU) Stock Rating Lowered by Zacks Investment Research

Share on StockTwits

AC Immune (NASDAQ:ACIU) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, reports.

According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “

Separately, HC Wainwright increased their target price on shares of AC Immune from $11.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, March 30th.

Shares of NASDAQ ACIU opened at $6.16 on Monday. The firm has a market cap of $447.54 million, a price-to-earnings ratio of -6.84 and a beta of 0.82. AC Immune has a 52-week low of $4.42 and a 52-week high of $13.00. The business’s 50 day moving average is $7.23 and its two-hundred day moving average is $6.32.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Tuesday, March 23rd. The company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.01). AC Immune had a negative net margin of 392.56% and a negative return on equity of 23.88%. The firm had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.27 million. On average, analysts predict that AC Immune will post -0.88 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. Engineers Gate Manager LP acquired a new stake in shares of AC Immune in the 4th quarter valued at $63,000. Virtu Financial LLC acquired a new position in shares of AC Immune during the 3rd quarter worth about $159,000. Squarepoint Ops LLC purchased a new position in shares of AC Immune in the 4th quarter valued at about $255,000. Banque Cantonale Vaudoise raised its position in shares of AC Immune by 4.5% during the 4th quarter. Banque Cantonale Vaudoise now owns 58,285 shares of the company’s stock worth $303,000 after acquiring an additional 2,516 shares in the last quarter. Finally, Morgan Stanley boosted its holdings in AC Immune by 89.6% in the third quarter. Morgan Stanley now owns 144,557 shares of the company’s stock valued at $706,000 after purchasing an additional 68,300 shares in the last quarter. Institutional investors own 27.68% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Recommended Story: What are municipal bonds?

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with's FREE daily email newsletter.